All information on this website is intended strictly for educational and research purposes only.
The content on OpenPep — including peptide profiles, clinical trial summaries, dosing information, and reconstitution calculators — must not be used for:
OpenPep aggregates publicly available clinical trial data and research. We do not sell, distribute, or recommend any substances. All AI-generated summaries are interpretations of published research and may contain errors.
Bremelanotide
For educational and research purposes only. Not medical advice.
PT-141 (Bremelanotide/Vyleesi) is FDA-approved for HSDD in premenopausal women. Clinical trials showed significant improvement in sexual desire scores. Unique mechanism works centrally through melanocortin pathways rather than vascular effects.
Best Time
45 min before desired effect
Method
subcutaneous
Frequency
As needed, 45 min before activity
Half-life
~2.7 hours
Cycle Length
As needed
Storage
Refrigerate at 2-8°C.
Published Dosing Ranges
Create an account to access peptide research data.
Contraindications
Create an account to access peptide research data.
Kisspeptin-10 stimulates GnRH release for upstream hormonal activation while PT-141 directly activates MC4R for sexual arousal. Different levels of the neuroendocrine axis — complementary for sexual health.
theoreticalOxytocin enhances bonding, arousal, and orgasm intensity while PT-141 addresses central nervous system arousal via melanocortin receptors. Different mechanisms for sexual enhancement.
communityBoth target melanocortin receptors. PT-141 is the selective MC4R agonist while Melanotan II is non-selective. Combining causes unpredictable receptor overstimulation.
documentedDrug development research 87 (3) :e70293 · 2026-05-01
2021-05-10
International journal of impotence research 16 (1) :51-9 · 2004-02-01
Current topics in medicinal chemistry 7 (11) :1098-1106 · 2007-01-01
Expert review of clinical pharmacology 18 (10) :1-13 · 2025-10-01
Mechanism of Action
Melanocortin-4 receptor agonist that works through the central nervous system to increase sexual desire, rather than acting on the vascular system like PDE5 inhibitors.
Reported by the community. These may not be supported by clinical evidence and are not medical recommendations.